El beso de la mujer araña regresa en su mejor versión lanacion.com.ar - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lanacion.com.ar Daily Mail and Mail on Sunday newspapers.
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Vicinity Motor Corp (CVE:VMC) (OTCQX:BUSXF) (FRA:6LG) reported a 588% year-over-year increase in its first quarter 2021 revenue to C$27.3 million as the company delivered 67 buses during the period, about 10 times more than a year ago. Vicinity also swung to a quarterly profit $2.0 million, or $0.07 per share, from a net loss of $1.7 million, or $0.07 per share, in the same quarter a year earlier.
Midwest Energy Emissions Corp (OTCQB:MEEC) (ME2C Environmental) reported its 1Q results showing a 171% bump in year-over-year revenue at $3 million for the quarter. The environmental technologies firm saw most of its revenue come from sorbent product sales, which hit $2 million. During the three-month period to end March 31, 2021, ME2C strengthened its balance sheet by eliminating $1.85 million in convertible debt.
MAPLE SHADE The fire department Friday said it is seeking legal action to get back in its fire hall and resume services following the township s decision to suspend the department for 90 days.
The news came a day after residents and community members demanded answers about the 90-day suspension of The Independent Fire Company No.1. Our building which is owned and deeded to Independent Fire Company No. 1 was illegally entered and seized by the Township Manager and council without any due process or notice. Our legal council is working diligently to get access to our building, the department said in a social media post Friday.
Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
The RECONNECT trial of the transdermal get is designed to evaluate its efficacy and safety in children and adolescents with FXS The company believes that the results, if positive, from RECONNECT will be sufficient to support the submission of a New Drug Application for Zygel
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS).
The trial, which will be called RECONNECT (A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome), is designed to evaluate the efficacy and safety of Zygel in children and adolescents with FXS.